Why a kidney disease drug approval in China is just the start for this S.F. company

To win its first-ever drug approval, FibroGen Inc. turned to China, but it's not going to be the San Francisco company's last stop.

China's drug regulatory agency Monday approved roxadustat, the first drug of its kind for dialysis patients with anemia caused by chronic kidney disease. San Francisco-based FibroGen's (NASDAQ: FGEN) China subsidiary will manufacture the tablet and partner AstraZeneca plc (NYSE: AZN) will sell the drug starting in the second-half of 2019.

But roxadustat's win in China…

Previous D.C. Council approves St. E's hospital bill after changes; GWU Hospital mum
Next Zane Burke lands CEO gig at Silicon Valley's fastest-growing private company

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *